Trevena

Trevena

PA - Chesterbrook
Biotechnology
WebsiteLinkedInCareers Page

Focus: GPCR-targeted Drug Discovery

Trevena is a life sciences company focused on GPCR-targeted Drug Discovery.

CardiovascularNeurology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

OLINVYK
oliceridine
Peak
INTRAVENOUS ยท SOLUTION
mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
for whom alternative treatments are inadequate
2020
0

Pipeline & Clinical Trials

Part A: TRV250-20mg/ml
Migraines
Phase 1
Clinical Trials (1)
NCT04201080A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250
Phase 1
Radiolabeled TRV130
Healthy
Phase 1
Clinical Trials (1)
NCT02169934A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects
Phase 1
TRV130 1.5 mg
Pain, Acute
Phase 1
Clinical Trials (1)
NCT02083315Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects
Phase 1
TRV130
Healthy
Phase 1
Clinical Trials (1)
NCT02344303Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals
Phase 1
TRV130A
Healthy
Phase 1
Clinical Trials (1)
NCT01514578Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males
Phase 1
TRV120027
Heart Failure
Phase 1
Clinical Trials (1)
NCT01444872Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction
Phase 1
Open-label TRV734 125 mg
Healthy
Phase 1
Clinical Trials (1)
NCT02211625A Safety, Tolerability, PD and PK Study in Healthy Adults
Phase 1
TRV734
Healthy
Phase 1
Clinical Trials (1)
NCT02411500A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males
Phase 1
TRV120027
Heart Failure
Phase 1/2
Clinical Trials (1)
NCT01187836Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure
Phase 1/2
Phase 2
Clinical Trials (1)
NCT02100748A Study of TRV130 for the Treatment of Pain After Bunionectomy
Phase 2
Phase 2
Clinical Trials (1)
NCT01966601A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure
Phase 2
TRV130
Pain
Phase 2
Clinical Trials (1)
NCT02335294A Study of TRV130 for the Treatment of Pain After Abdominoplasty
Phase 2
TRV130
Pain
Phase 2
Clinical Trials (1)
NCT02520297A Pilot Study of TRV130 for the Treatment of Fracture Pain
Phase 2
Oliceridine
Acute Pain
Phase 3
Clinical Trials (1)
NCT02820324Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Phase 3
Oliceridine
Acute Pain
Phase 3
Clinical Trials (1)
NCT02815709Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Phase 3
Phase 3
Clinical Trials (1)
NCT02656875A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 16 clinical trials
Top TAs: Cardiovascular, Nephrology, Neurology
Publications: 25 in PubMed
Portfolio Health
Peak1 (100%)
1 total products
Therapeutic Area Focus
Cardiovascular
3 pipeline
Nephrology
1 pipeline
Neurology
1 pipeline
Marketed
Pipeline